EndocrineIn Stock
Tesamorelin
Stabilised GHRH Analogue
20mg · Lyophilised Powder
$129.00
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is the only GHRH analogue to have received FDA approval (for HIV-associated lipodystrophy), providing a well-characterised research profile with extensive clinical trial data.
Form
Lyophilised Powder
Purity
≥99% (HPLC)
Storage
2–8°C / 36–46°F
Use
Research Only
1
Secure checkout via PayID · Free shipping over $150
Research Overview
Tesamorelin (trans-3-hexenoic acid-GRF(1-44)-NH₂) is a stabilised analogue of endogenous growth hormone-releasing hormone (GHRH) with a modified N-terminus that confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, substantially extending its half-life compared to native GHRH.
Tesamorelin holds the distinction of being the only GHRH analogue to receive FDA approval, granted in 2010 for reducing excess abdominal fat in HIV-positive patients with lipodystrophy (EGRIFTA®, Theratechnologies Inc.). This regulatory status reflects an extensive clinical evidence base.
The pivotal Phase 3 trials (Falutz et al., NEJM 2007) demonstrated significant reductions in visceral adipose tissue as measured by CT scan, alongside improvements in lipid profiles and patient-reported outcomes.
Research interest in tesamorelin has expanded to examine its effects on cognitive function. A notable randomised controlled trial (Baker et al., 2021) investigated tesamorelin's effects on cognition in older adults with mild cognitive impairment, reporting improvements in executive function and verbal memory — hypothesised to be mediated through IGF-1 signalling in the central nervous system.
Research Use Only
For in vitro research and laboratory use only. Not approved by the TGA, FDA, or any regulatory authority for human or veterinary use. By purchasing, you confirm you are a qualified researcher using this compound solely for lawful scientific research.
